Stock Info Nets

Independent Financial Information Made Easy

Our AI creates

The Best Stock Graphs and Charts

Youtube Subscribe Blog GamificArt

The development of Artificial Intelligence (AI) is modifying the way investments are evaluated. We programmed an artificial intelligence (A.I.) to summarize the whole internet. Whether you’re trying to make money investing online, making financial decisions or just getting informed about Wall Street, this page is a way to get informed without reading hundred of pages. Our stock market summary graphs are produced using machine learning, an unbiased view to capture what internet is saying. Usually, the AI reads several hundred pages and summarize it to a short text and several charts.

September 21, 2023 22:18 (London Time)

Biogen

Youtube Subscribe

...

Sector: Biotechnology
Ticker: BIIB
Sentiment: 0.7579
MarketCap: 37,730,823,467.0
High: 260.27 Low: 256.88

Open: 258.8 Close: 258.93 Change: 0.13

Don't invest in Biogen Company Inc Stock before reading this automated analysis produce by an AI.

This document will help you to evaluate Biogen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, inc, stock, market, stockholder, approve, merger, and the …

Concept Map

...

Semantic Network

...

Stock Summary

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, AVonEX, PLE.

Today's Summary

Reata Pharmaceuticals stockholders approve merger transaction with Biogen inc. (NASDAQ:BIIB) The 98 analysts offering price forecasts for Biogen stock have a median target of 312.90.

Today's News

Biogen inc. stock falls thursday, still outperforms market - marketwatch.com. Biogen Inc. stock fell thursday. Biib inc. (biib) stock sinks as market gains: what you should know. Reata Pharmaceuticals stockholders approve merger transaction with biogen inc. reata pharmaceuticals stockholder approve merger. Biogen Inc. (NASDAQ:BIIB) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? Toroso Investments LLCs holdings in Biogen were worth $2,522,000 at the end of the most recent reporting period. Reata Pharmaceuticals stockholders approve merger transaction with Biogen inc. (NASDAQ:BIIB) The 98 analysts offering price forecasts for Biogen stock have a median target of 312.90, with a high estimate of 381.00 and a low estimate of 200.00. The high in the last 52 weeks of Biogen is 319.76. $100 invested in biogen 15 years ago would be worth this much today - biogen (nasdaq:biib) Currently, Biogen has a market capitalization of $37.04 billion.

Stock Profile

"Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts."

Keywords

The game is changing. There is a new strategy to evaluate Biogen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, inc, stock, market, stockholder, approve, merger, and the most common words in the summary are: biogen, stock, market, news, top, price, inc, . One of the sentences in the summary was: Reata Pharmaceuticals stockholders approve merger transaction with Biogen inc. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #biogen #stock #market #news #top #price #inc.

Read more →

Related Results

...
March 10, 2024 10:00 (London Time)

Biogen

21 analysts provided ratings for Biogen (NASDAQ:BIIB), showcasing a mix of bullish and bearish perspectives. Donanemab, if approved, would follow Ei…
Sector: Biotechnology
Ticker: BIIB
Sentiment: 0.9834
MarketCap: 32,447,437,329.0
High: 228.36 Low: 221.98

Open: 225.45 Close: 223.24 Change: -2.21

Read more →
...
January 25, 2024 23:38 (London Time)

Biogen

Biogen stock slips as ubs downgrades (nasdaq:biib) | seeking alpha. biogen stock slip as uBS downgrades. Biogen slips as UBS cuts to Neutral on Alzh…
Sector: Biotechnology
Ticker: BIIB
Sentiment: 0.8885
MarketCap: 35,795,629,588.0
High: 249.46 Low: 245.25

Open: 247.22 Close: 246.21 Change: -1.01

Read more →
...
January 20, 2024 11:46 (London Time)

Biogen

Real estate brokers for the company are marketing about 114,000 square feet of office space at the six-story 225 Binney St. The current Biogen share…
Sector: Biotechnology
Ticker: BIIB
Sentiment: 0.7783
MarketCap: 36,218,732,075.0
High: 251.28 Low: 244.43

Open: 246.96 Close: 249.96 Change: 3.0

Read more →
...
December 11, 2023 0:23 (London Time)

Biogen

Cowen believes Biogen ( NASDAQ: BIIB ) is set to perform well next year and has named the stock one of its top picks for 2024. Cowen admits that the…
Sector: Biotechnology
Ticker: BIIB
Sentiment: 0.8885
MarketCap: 34,672,669,220.0
High: 240.81 Low: 236.8

Open: 237.65 Close: 239.29 Change: 1.64

Read more →
...
September 21, 2023 22:18 (London Time)

Biogen

Reata Pharmaceuticals stockholders approve merger transaction with Biogen inc. (NASDAQ:BIIB) The 98 analysts offering price forecasts for Biogen sto…
Sector: Biotechnology
Ticker: BIIB
Sentiment: 0.7579
MarketCap: 37,730,823,467.0
High: 260.27 Low: 256.88

Open: 258.8 Close: 258.93 Change: 0.13

Read more →
...
September 01, 2023 6:02 (London Time)

Biogen

SAGE Therapeutics plans to lay off about 188 people, or about 40% of its workforce. Biogen generated $2.46 billion during this quarter.
Sector: Biotechnology
Ticker: BIIB
Sentiment: 0.8442
MarketCap: 38,721,415,078.0
High: 269.18 Low: 265.32

Open: 266.83 Close: 267.36 Change: 0.53

Read more →
...
July 14, 2023 8:56 (London Time)

Biogen

Biogen (NASDAQ: BIIB) stock is up 0.5% premarket on Monday. Leqembi won a coveted standard approval nod from the U.S. FDA granted accelerated approv…
Sector: Biotechnology
Ticker: BIIB
Sentiment: 0.9906
MarketCap: 40,234,036,032.0
High: 280.86 Low: 276.4

Open: 278.93 Close: 277.97 Change: -0.96

Read more →
...
June 15, 2023 20:35 (London Time)

Biogen

Biogen Inc. last traded at just under $309, where they closed Thursday. FDA AdCom has unanimously voted in favour of Biogen and Eisais Leqembi in Al…
Sector: Biotechnology
Ticker: BIIB
Sentiment: 0.9934
MarketCap: 43,421,262,976.0
High: 299.99 Low: 293.21

Open: 299.77 Close: 297.83 Change: -1.94

Read more →
...
January 31, 2024 19:56 (London Time)

Biogen

Biogen has terminated the licence agreement for the drug Aduhelm, with rights now reverting to the original owner, Swiss biopharma Neurimmune. The F…
Sector: Biotechnology
Ticker: BIIB
Sentiment: 0.9153
MarketCap: 35,801,425,512.0
High: 251.99 Low: 247.04

Open: 247.67 Close: 248.39 Change: 0.72

Read more →
...
January 23, 2024 20:23 (London Time)

Biogen

Evelo Biosciences announced it is cutting its workforce.
Sector: Biotechnology
Ticker: BIIB
Sentiment: 0.9565
MarketCap: 35,978,201,209.0
High: 251.4 Low: 248.01

Open: 249.13 Close: 251.18 Change: 2.05

Read more →
...
January 06, 2024 18:31 (London Time)

Biogen

Biogen Inc. stock outperforms fr Friday when compared to competitors. At the time, Biogen had just launched a sweeping cost-reduction program that i…
Sector: Biotechnology
Ticker: BIIB
Sentiment: 0.9403
MarketCap: 37,366,325,122.0
High: 259.93 Low: 255.38

Open: 257.47 Close: 257.88 Change: 0.41

Read more →
...
October 29, 2023 11:57 (London Time)

Biogen

An injected version of Eisai (4523.T) and Biogen (BIIB) Alzheimers drug Leqembi works as well as the current intravenous version at removing toxic b…
Sector: Biotechnology
Ticker: BIIB
Sentiment: 0.8555
MarketCap: 33,963,968,524.0
High: 240.28 Low: 233.76

Open: 240.0 Close: 234.52 Change: -5.48

Read more →
...
September 14, 2023 2:53 (London Time)

Biogen

Bridger Management LLC grew its holdings in shares of Biogen Inc. (NASDAQ:BIIB) in the first quarter. Tysabri, an anti-α4 integrin monoclonal antibo…
Sector: Biotechnology
Ticker: BIIB
Sentiment: 0.9648
MarketCap: 37,061,739,659.0
High: 260.0 Low: 255.05

Open: 258.62 Close: 255.91 Change: -2.71

Read more →
...
August 06, 2023 1:11 (London Time)

Biogen

Biogen has agreed to acquire Reata Pharmaceuticals for a total of $7.3 billion. Decision to buy Reata signals a new era under CEO Chris.
Sector: Biotechnology
Ticker: BIIB
Sentiment: 0.584
MarketCap: 39,000,924,115.0
High: 269.94 Low: 266.68

Open: 267.04 Close: 268.92 Change: 1.88

Read more →
...
July 13, 2023 4:49 (London Time)

Biogen

Eisai (4523.T) and Biogen (BIIB) Leqembi won a coveted standard approval nod from the U.S. FDA grants standard approval of eisai/biogen alzheimers d…
Sector: Biotechnology
Ticker: BIIB
Sentiment: 0.9623
MarketCap: 40,183,376,204.0
High: 281.68 Low: 277.29

Open: 280.17 Close: 277.62 Change: -2.55

Read more →
...
May 11, 2023 18:17 (London Time)

Biogen

Biogen stock was originally listed at a price of $5.73 in Dec 31, 1997. Biogen-Idec is a company based in Ireland and focuses on neurology, immunolo…
Sector: Biotechnology
Ticker: BIIB
Sentiment: 0.9413
MarketCap: 40,804,191,286.0
High: 313.59 Low: 309.71

Open: 313.5 Close: 310.12 Change: -3.38

Read more →